查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1806127

全球干细胞市场（按细胞类型、细胞来源、技术、应用和最终用户划分）预测 2025-2030

Stem Cells Market by Cell Type, Cell Source, Technology, Cell Source, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年干细胞市场规模将达到142.2亿美元，2025年将达到157.2亿美元，复合年增长率为10.89%，到2030年将达到264.5亿美元。

主要市场统计数据
基准年2024年 142.2亿美元
预计2025年 157.2亿美元
预测年份 2030 264.5亿美元
复合年增长率（%） 10.89%

揭示干细胞创新在治疗研究和临床应用的变革力量和新可能性

干细胞技术已迅速从学术好奇心发展成为治疗创新的前沿，推动了再生医学、药物研发和基础生物学等领域的突破性进展。从人类胚胎干细胞的开创性分离到诱导性多功能干细胞的现代掌握，该领域如今已支持各种临床试验和商业计画。对细胞分化、微环境工程和免疫调节的深入研究展现了这些活体疗法的多方面潜力，为心血管疾病、神经退化性疾病和组织损伤提供了潜在的治疗方法。

监管进步、技术创新和策略合作正在引领模式转移并重塑干细胞领域

在监管发展、技术突破和策略合作的推动下，干细胞生态系统正在经历模式转移。全球卫生部门的新指南在病人安全与再生疗法快速通道之间取得平衡，从而加速核准并实施同情用药计画。同时，CRISPR 平台和整合定序等基因组工程的突破，正在实现对细胞身份和功能的前所未有的控制。

分析2025年美国关税对干细胞供应链和研究趋势的广泛累积影响

美国将于2025年加征关税，这为全球干细胞供应链和研究活动带来了巨大的复杂性。虽然这些措施旨在保护国内製造业，但也影响了细胞培养、基因编辑和生物列印过程中所需的试剂、专用设备和原料的采购。因此，实验室和生产设施面临进口成本上升的问题，迫使采购团队寻找替代供应商和本地生产合作伙伴，以缓解预算压力。

释放细胞类型、来源、技术、应用和最终用户的关键细分洞察，以揭示市场机会

深入研究细分洞察，揭示出由多种细胞类型分类、来源、技术平台、组织输入、应用和最终用户类别所塑造的微妙模式。研究细胞类型后发现，成体干细胞、诱导性多功能干细胞的发展轨迹截然不同。进一步按细胞来源细分，对比了同种异体疗法和自体疗法，突显了现成可用性与个人化适用性之间的权衡。

检验区域动态，重点关注美洲、欧洲、中东和非洲以及亚太地区的新兴驱动力和挑战

干细胞领域的区域动态揭示了正在塑造全球应用模式的成长轨迹、创新丛集和法律规范。美洲成熟市场拥有强大的临床试验和生产基础设施，这得益于资金雄厚的研究机构和成熟的生物製药公司。该地区的监管机构持续完善快速通道，在病患安全与快速取得先进治疗方法之间取得平衡。跨境合作和共用创新中心进一步连结了生态系统。

分析影响全球干细胞研究市场竞争动态的主要企业的策略创新和联盟

领先的干细胞公司正在部署差异化策略，透过将深厚的科学研究专长与强大的伙伴关係网路和敏捷的经营模式相结合，获得竞争优势。一些大型生物製药公司已经整合了端到端平台，连接上游细胞采购、基因编辑能力和下游製造，确保整个价值链的一致性和可追溯性。这些整合型公司通常会与专业技术公司达成许可和共同开发契约，以加速产品线多元化并缩短临床开发时间。

为行业领导者制定可行的建议，以促进永续成长、推动创新并应对不断变化的监管和市场趋势。

为了在不断发展的干细胞生态系统中保持发展势头，行业领导者应采取积极主动的多学科方法，将科学创新与卓越营运和监管敏锐性相协调。首先，他们必须投资一个整合的数位框架，该框架将来自研发、製造和临床营运的数据集中起来，实现即时决策和预测分析，并简化工作流程。同时，他们必须建立跨职能的管治团队，以确保从计划启动到商业化的整个过程中，监管要求、品质标准和伦理考量都得以执行。

了解我们全面的调查方法，该方法整合了资料来源、相关人员的参与和分析框架，从而提供可靠的干细胞市场情报

本报告的调查方法融合了定性和定量分析，以捕捉干细胞领域的多面性。初步的二次研究包括深入查阅同行评审期刊、监管格局、专利格局、会议论文集和技术白皮书，以绘製科学进步和政策发展图景。这些见解与专有资料库和行业出版物相结合，以检验新兴趋势并识别主要企业。

主要发现摘要：对干细胞生态系统和转化研究相关人员的策略意义和未来前景

本执行摘要总结了关于干细胞研究这一蓬勃发展领域及其在医疗创新中日益扩大的作用的关键见解。它探讨了新的监管措施、技术进步和策略合作如何重塑这一格局，以及新征收的关税如何影响供应链和研究的连续性。详细的細項分析检验了不同细胞类型、来源、技术、组织投入、应用和最终用户的市场规模差异，为相关人员提供了有针对性的切入点和閒置频段机会。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 诱导多功能细胞在个人化疾病建模和高通量药物筛检的进展
  • 使用无支架干细胞球体生物列印功能组织用于复杂器官再生
  • 针对发炎性肠道疾病症状的同种异体间质干细胞疗法的快速发展
  • CRISPR编辑造血干细胞疗法的出现，用于治疗镰状细胞疾病併发症
  • 同种异体神经干细胞移植在脊髓损伤修復通讯协定中首次获得监管部门核准
  • 基于干细胞分泌组衍生的细胞外囊泡的诊断技术商业化用于早期疾病检测
  • 生技创新者与製药公司建立策略联盟，加速以干细胞为基础的心臟衰竭治疗
  • 自动化干细胞製造平台的投资趋势，旨在扩大生产规模并降低治疗成本
  • 整合人工智慧驱动的预测分化模型，用于干细胞生产的品管
  • 开发用于癌症治疗的现成CAR-T细胞疗法，该疗法源自于诱导多功能细胞

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章 干细胞市场（依细胞类型）

  • 成体干细胞
  • 人类胚胎干细胞
  • 诱导性多功能细胞

第九章干细胞市场：细胞来源

  • 同种异体
  • 自体移植

第 10 章 干细胞市场：依技术

  • 生物列印
  • 细胞培养
    • 2D文化
    • 3D文化
  • 基因编辑
    • CRISPR
    • 转录活化因子样效应核酸酶

第 11 章 干细胞市场：依细胞来源

  • 脂肪组织
  • 羊膜细胞
  • 骨髓
  • 週边血
  • 脐带

第 12 章干细胞市场：依应用

  • 细胞库
    • 私人银行
    • 公营银行
  • 药物研发与测试
    • 药物筛检
    • 毒性测试
  • 再生医学
    • 心血管系统
    • 神经病学
    • 整形外科
  • 研究与开发

第十三章 干细胞市场（依最终用户）

  • 生物製药公司
  • 受託研究机构
  • 医院和诊所
  • 研究所

14.美洲干细胞市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 欧洲、中东和非洲干细胞市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

16.亚太干细胞市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Danaher Corporation
    • Charles River Laboratories International, Inc.
    • Advanced Cell Technology, Inc.
    • AlloSource, Inc.
    • Anterogen Co., Ltd.
    • Athersys Inc.
    • Becton, Dickinson and Company
    • Bioheart Inc.
    • Biorestorative Therapies Inc.
    • BrainStorm Cell Therapeutics Inc.
    • Bristol-Myers Squibb Company
    • Cellartis AB
    • Cellular Engineering Technologies Inc.
    • Gamida Cell Ltd
    • GE HealthCare by General Electric Company
    • GenScript Biotech Corporation
    • Gilead Sciences, Inc.
    • HOLOSTEM Srl by Chiesi Farmaceutici SpA
    • JCR Pharmaceuticals Co., Ltd.
    • Lineage Cell Therapeutics, Inc.
    • Lonza Group
    • Merck KGaA
    • Novartis AG
    • Novo Holdings A/S
    • NuVasive Inc.
    • Pluristyx, Inc.
    • Sartorius AG
    • STEMCELL Group of Companies
    • Takeda Pharmaceutical Company Limited
    • Thermo Fisher Scientific Inc.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-434CCDA04CF2

The Stem Cells Market was valued at USD 14.22 billion in 2024 and is projected to grow to USD 15.72 billion in 2025, with a CAGR of 10.89%, reaching USD 26.45 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 14.22 billion
Estimated Year [2025] USD 15.72 billion
Forecast Year [2030] USD 26.45 billion
CAGR (%) 10.89%

Unveiling the Transformative Power and Emerging Potential of Stem Cell Innovations Across Therapeutic Research and Clinical Applications

Stem cell technologies have rapidly ascended from academic curiosities to the forefront of therapeutic innovation, fueling breakthroughs across regenerative medicine, drug discovery, and fundamental biology. Spanning the pioneering isolation of human embryonic stem cells to the contemporary mastery of induced pluripotent stem cells, this domain now underpins a wide array of clinical trials and commercial ventures. Insights into cellular differentiation, niche engineering, and immune modulation contextualize the multifaceted promise of these living therapeutics, offering potential treatments for cardiovascular disease, neurodegenerative disorders, and tissue injuries.

Amid growing demand for personalized medicine and precision therapies, stem cell platforms have attracted substantial investment, catalyzing collaborations between biopharma companies, research institutes, and technology providers. Simultaneously, advancements in culture systems, gene editing, and bioprinting have expanded both the scale and fidelity of cell-based processes, transitioning novel concepts from bench to bioreactor. Against a backdrop of increasingly complex regulations and evolving reimbursement models, organizations must navigate dynamic scientific, commercial, and policy landscapes to capture value.

This introduction frames a comprehensive exploration of core market drivers, disruptive shifts, tariff impacts, segmentation nuances, regional variances, company strategies, and actionable recommendations. By charting the intersecting trajectories of technology, policy, and enterprise initiatives, readers gain a cohesive understanding of how stem cell innovations are reshaping the future of healthcare and life sciences.

Charting Paradigm Shifts Driven by Regulatory Advances, Technological Breakthroughs, and Strategic Collaborations Reshaping the Stem Cell Landscape

The stem cell ecosystem is undergoing paradigm shifts fueled by regulatory advancements, technological breakthroughs, and strategic alliances. Emerging guidance from global health authorities now balances patient safety with expedited pathways for regenerative therapies, enabling accelerated approvals and compassionate use programs. In parallel, breakthroughs in genome engineering, such as enhanced CRISPR platforms and integrative sequencing, have unlocked unprecedented control over cellular identity and function.

Technological maturation of bioprinting, microfluidic culture systems, and organ-on-chip models is redefining tissue engineering, while novel biomaterials offer optimized scaffolding that mimics native extracellular matrices. These innovations, in turn, propel downstream applications such as drug screening, toxicity assessment, and personalized therapeutics. Meanwhile, large-scale manufacturing paradigms, including automated closed-loop bioreactors and real-time analytics, are shifting production from pilot stage to commercial viability.

Strategic collaborations between pharmaceutical developers, device manufacturers, academic laboratories, and contract research organizations are accelerating de-risking of complex projects. Consortium models, shared IP frameworks, and co-development agreements are breaking traditional silos, fostering co-innovation to tackle clinical translation challenges. As stakeholders adopt integrated development approaches, they are realigning investment portfolios and forging new value chains. These transformative shifts collectively reshape the competitive landscape, establishing a foundation for the next wave of stem cell-driven healthcare solutions and reshaping expectations around efficacy, safety, and scalability.

Analyzing the Extensive Cumulative Impact of United States Tariffs Implemented in 2025 on Stem Cell Supply Chains and Research Dynamics

The introduction of United States tariffs in 2025 has introduced notable complexities across global stem cell supply chains and research operations. While aimed at protecting domestic manufacturing sectors, these measures have reverberated through the procurement of essential reagents, specialized equipment, and raw materials critical to cell culture, gene editing, and bioprinting processes. Consequently, laboratories and production facilities have confronted increased costs for imported items, prompting procurement teams to explore alternative suppliers or local manufacturing partners to mitigate budgetary pressures.

Operational delays have emerged as shipment schedules adjust to new customs protocols, extending lead times for key consumables such as growth factors, culture media, and high-precision instrumentation. These disruptions carry significant implications for time-sensitive experiments and ongoing clinical trial activities, where consistency and reproducibility are paramount. Organizations that had built just-in-time inventory strategies now reassess safety stock levels and distribution networks to maintain continuity under evolving tariff regimes.

In response, strategic buyers are intensifying collaboration with domestic distributors to secure favorable terms, while some academic and commercial entities are repatriating portions of their supply chains to reclaim cost certainty. In parallel, industry stakeholders are lobbying for tariff exemptions on biotechnology essentials, advocating the critical nature of these materials in advancing human health. The cumulative impact of these policies underscores the importance of supply chain resilience and adaptive sourcing strategies as foundational elements of sustainable stem cell research and manufacturing.

Unlocking Key Segmentation Insights Spanning Cell Types Sources Technologies Applications and End Users to Illuminate Market Opportunities

Diving into segmentation insights reveals a nuanced landscape shaped by diverse cell type classifications, source origins, technology platforms, tissue inputs, applications, and end user categories. Examining cell types illustrates the distinct trajectories of adult stem cells alongside human embryonic stem cells and induced pluripotent stem cells, each offering unique advantages in differentiation potential, ethical considerations, and scalability. Further segmentation according to cell source contrasts allogeneic therapies with autologous approaches, delineating trade-offs between off-the-shelf availability and personalized compatibility.

Technological segmentation uncovers the rapid ascendance of bioprinting alongside advanced cell culture methodologies, with two-dimensional systems evolving into physiologically relevant three-dimensional environments. Concurrently, gene editing technologies, anchored by CRISPR advancements and transcription activator-like effector nucleases, enable precision modifications that enhance therapeutic efficacy and safety. Tissue source segmentation highlights critical material inputs such as adipose tissue, amniotic cells, bone marrow, peripheral blood, and umbilical cord, each presenting specific extraction, expansion, and regulatory considerations.

From an application standpoint, cell banking divides into private and public repositories, while drug discovery and testing programs leverage pharmaceutical screening and toxicity assays to de-risk novel compounds. Regenerative medicine projects target cardiovascular, neurological, and orthopedic indications, reflecting both unmet clinical needs and reimbursement landscapes. Finally, end users spanning biopharmaceutical companies, contract research organizations, hospitals and clinics, and research institutes drive demand patterns and service offerings. This multifaceted segmentation framework provides stakeholders with granular touchpoints to tailor strategies, optimize resource allocation, and uncover white-space opportunities across the evolving stem cell market.

Examining Regional Dynamics Highlighting Emerging Growth Drivers and Distinct Challenges Across the Americas Europe Middle East Africa and Asia Pacific

Regional dynamics in the stem cell arena reveal varied growth trajectories, innovation clusters, and regulatory frameworks that shape global adoption patterns. Within the Americas, mature markets exhibit robust infrastructure for clinical trials and manufacturing, anchored by well-funded research institutes and established biopharma players. Regulatory agencies in this region continue to refine expedited pathways, striking a balance between patient safety and accelerated access to pioneering therapies. Cross-border collaborations and shared innovation hubs further bolster ecosystem connectivity.

In Europe, Middle East and Africa, a mosaic of regulatory approaches underscores the complexity of harmonizing standards across multiple jurisdictions. While certain European nations spearhead adaptive licensing schemes and advanced therapy classifications, emerging markets in the Middle East and Africa are cultivating nascent research centers and investment incentives. Stakeholders in this region navigate intricate compliance landscapes while capitalizing on expanding public and private funding opportunities.

Asia-Pacific stands out as a vibrant frontier, driven by rapid technological adoption, supportive government policies, and growing interest in regenerative solutions. Countries across this region are streamlining approval processes and investing heavily in domestic biomanufacturing capabilities. Strategic partnerships between multinational corporations and local players accelerate technology transfer and capacity building, positioning Asia-Pacific for a significant share of future advances. Recognizing these regional nuances enables organizations to align market entry strategies, prioritize regulatory pathways, and adapt commercial models for sustainable growth across diverse geographies.

Dissecting Leading Company Strategies Innovations and Collaborations Shaping Competitive Dynamics within the Global Stem Cell Research Market

Leading organizations within the stem cell domain are deploying differentiated strategies to gain competitive advantage, combining deep scientific expertise with robust partnership networks and agile business models. Some of the foremost biopharmaceutical companies are integrating end-to-end platforms that link upstream cell sourcing, gene editing capabilities, and downstream manufacturing, thereby ensuring consistency and traceability across the value chain. These integrated players often pursue in-licensing arrangements and co-development deals with specialized technology firms to accelerate pipeline diversification and reduce time-to-clinic.

Contract research organizations and cell therapy contract manufacturers have expanded service portfolios to include process development, scale-up expertise, and regulatory consulting, recognizing that turnkey solutions foster stronger client relationships and higher entry barriers for competitors. Simultaneously, academic spin-outs and small biotech ventures are forging strategic alliances with larger incumbents to secure capital, access specialized facilities, and navigate complex approval pathways. These collaborations frequently involve milestone-based licensing agreements and shared risk-reward frameworks.

Moreover, technology innovators in bioprinting and advanced culture systems are partnering with biopharma giants to co-create next-generation test platforms that reduce reliance on animal models while offering human-relevant data. Company strategies increasingly emphasize flexible manufacturing modules, digital twins, and real-time analytics, enabling rapid process optimization and lower operational costs. By examining these company initiatives, stakeholders can benchmark best practices, identify potential partners, and anticipate shifts in competitive positioning driven by novel alliances and platform expansions.

Formulating Actionable Recommendations for Industry Leaders to Foster Sustainable Growth Drive Innovation and Navigate Evolving Regulatory and Market Trends

To maintain momentum in the evolving stem cell ecosystem, industry leaders should adopt a proactive, multidisciplinary approach that aligns scientific innovation with operational excellence and regulatory acumen. Firstly, organizations must invest in integrated digital frameworks that unify data from R&D, manufacturing, and clinical operations, empowering real-time decision-making and predictive analytics to streamline workflows. Concurrently, establishing cross-functional governance teams ensures that regulatory requirements, quality standards, and ethical considerations are embedded from project inception through commercialization.

Secondly, strategic sourcing initiatives should prioritize supply chain resilience by cultivating diverse vendor relationships, localizing critical material production, and implementing advanced inventory management systems. This mitigates exposure to external policy shifts, such as tariffs, and enhances continuity of research and manufacturing activities. Thirdly, fostering collaborative innovation through consortium models and public-private partnerships accelerates technology validation and de-risking, while shared IP frameworks promote broader adoption of best-in-class methodologies.

Additionally, companies should align portfolio decisions with patient and payer perspectives, integrating health economics and outcomes research early in development to support value propositions. Tailored engagement with regulators, including adaptive trial designs and rolling submissions, can expedite approvals while maintaining rigorous safety standards. Finally, cultivating talent pipelines that blend expertise in cell biology, bioengineering, data science, and regulatory strategy will underpin sustained leadership. By implementing these actionable recommendations, stakeholders can navigate complexity, unlock new market segments, and drive tangible impact across the stem cell landscape.

Detailing Comprehensive Research Methodology Integrating Data Sources Stakeholder Engagement and Analytical Frameworks for Robust Stem Cell Market Intelligence

The research methodology underpinning this report integrates a blend of qualitative and quantitative approaches designed to capture the multifaceted nature of the stem cell sector. Initial secondary research involved exhaustive reviews of peer-reviewed journals, regulatory filings, patent landscapes, conference proceedings, and technology white papers to map scientific advancements and policy developments. These insights were triangulated with proprietary databases and trade publications to validate emerging trends and identify leading players.

Complementing secondary sources, primary research encompassed in-depth interviews with senior executives, R&D leaders, manufacturing specialists, regulatory authorities, and end users across biopharmaceutical companies, contract research organizations, hospitals, and research institutes. These dialogues provided context on strategic priorities, investment horizons, technology adoption drivers, and operational challenges. Survey instruments were deployed to capture quantitative measures related to segmentation parameters, regional priorities, and tariff impact perceptions.

Analytical frameworks such as Porter's Five Forces and SWOT analyses were applied to evaluate competitive pressures and organizational strengths. Segmentation modeling was conducted by synthesizing cell type, cell source, technology, tissue source, application, and end user dimensions, enabling granular scenario planning. Regional assessments incorporated macroeconomic indicators, regulatory indices, and healthcare infrastructure metrics. Iterative validation sessions with domain experts ensured the robustness of findings and the practical relevance of recommendations. This comprehensive research methodology delivers a holistic, evidence-based view of the global stem cell market ecosystem.

Summarizing Key Findings Strategic Implications and Future Outlook for Stakeholders Engaged in the Stem Cell Ecosystem and Translational Research Endeavors

This executive summary has distilled key insights into the dynamic field of stem cell research and its expanding role in healthcare innovation. We have examined how emerging regulatory pathways, technological breakthroughs, and strategic collaborations are collectively reshaping the landscape, while assessing the reverberations of newly imposed tariffs on supply chains and research continuity. A detailed segmentation analysis has illuminated discrete market dimensions across cell types, sources, technologies, tissue inputs, applications, and end users, offering stakeholders targeted entry points and white-space opportunities.

Regional insights spotlight the maturing infrastructures of the Americas, the regulatory diversity of Europe, Middle East and Africa, and the rapid ascendance of the Asia-Pacific region as a hub for both innovation and scale. Company profiles reveal an ecosystem where integrated platforms, consortium models, and agile manufacturing strategies define competitive positioning. Actionable recommendations emphasize integrated data frameworks, supply chain resilience, collaborative innovation, patient-centric portfolio alignment, and adaptive regulatory engagement as cornerstones for sustained leadership.

Collectively, these findings underscore a moment of inflection for the stem cell sector, where scientific promise converges with commercial pragmatism and policy momentum. By leveraging the insights, methodologies, and strategic imperatives outlined here, stakeholders can refine their roadmaps, mitigate risks, and accelerate the translation of cell-based therapies from concept to clinic. The future of regenerative medicine hinges on these convergent efforts, heralding a new era of human-centred therapeutic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Advances in induced pluripotent stem cells for personalized disease modeling and high throughput drug screening
  • 5.2. Bioprinting of functional tissues using scaffold free stem cell spheroids for complex organ regeneration
  • 5.3. Rapid development of allogeneic mesenchymal stem cell therapies targeting inflammatory bowel disease symptoms
  • 5.4. Emergence of CRISPR edited hematopoietic stem cell therapies for treatment of sickle cell disease complications
  • 5.5. First regulatory clearances for allogeneic neural stem cell implants in spinal cord injury repair protocols
  • 5.6. Commercialization of extracellular vesicle based diagnostics derived from stem cell secretome for early disease detection
  • 5.7. Strategic partnerships between biotech innovators and pharmaceutical companies to accelerate stem cell heart failure treatments
  • 5.8. Investment trends in automated stem cell manufacturing platforms to scale production and reduce therapy costs
  • 5.9. Integration of artificial intelligence driven predictive differentiation models for quality control in stem cell production
  • 5.10. Development of off the shelf CAR T cell therapies derived from induced pluripotent stem cells for cancer treatment

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Stem Cells Market, by Cell Type

  • 8.1. Introduction
  • 8.2. Adult Stem Cells
  • 8.3. Human Embryonic Stem Cells
  • 8.4. Induced Pluripotent Stem Cells

9. Stem Cells Market, by Cell Source

  • 9.1. Introduction
  • 9.2. Allogeneic
  • 9.3. Autologous

10. Stem Cells Market, by Technology

  • 10.1. Introduction
  • 10.2. Bioprinting
  • 10.3. Cell Culture
    • 10.3.1. 2D Culture
    • 10.3.2. 3D Culture
  • 10.4. Gene Editing
    • 10.4.1. CRISPR
    • 10.4.2. Transcription Activator-Like Effector Nuclease

11. Stem Cells Market, by Cell Source

  • 11.1. Introduction
  • 11.2. Adipose Tissue
  • 11.3. Amniotic Cells
  • 11.4. Bone Marrow
  • 11.5. Peripheral Blood
  • 11.6. Umbilical Cord

12. Stem Cells Market, by Application

  • 12.1. Introduction
  • 12.2. Cell Banking
    • 12.2.1. Private Banking
    • 12.2.2. Public Banking
  • 12.3. Drug Discovery & Testing
    • 12.3.1. Pharmaceutical Screening
    • 12.3.2. Toxicity Testing
  • 12.4. Regenerative Medicine
    • 12.4.1. Cardiovascular
    • 12.4.2. Neurology
    • 12.4.3. Orthopaedics
  • 12.5. Research & Development

13. Stem Cells Market, by End User

  • 13.1. Introduction
  • 13.2. Biopharmaceutical Companies
  • 13.3. Contract Research Organizations
  • 13.4. Hospitals & Clinics
  • 13.5. Research Institutes

14. Americas Stem Cells Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Stem Cells Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Stem Cells Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Danaher Corporation
    • 17.3.2. Charles River Laboratories International, Inc.
    • 17.3.3. Advanced Cell Technology, Inc.
    • 17.3.4. AlloSource, Inc.
    • 17.3.5. Anterogen Co., Ltd.
    • 17.3.6. Athersys Inc.
    • 17.3.7. Becton, Dickinson and Company
    • 17.3.8. Bioheart Inc.
    • 17.3.9. Biorestorative Therapies Inc.
    • 17.3.10. BrainStorm Cell Therapeutics Inc.
    • 17.3.11. Bristol-Myers Squibb Company
    • 17.3.12. Cellartis AB
    • 17.3.13. Cellular Engineering Technologies Inc.
    • 17.3.14. Gamida Cell Ltd
    • 17.3.15. GE HealthCare by General Electric Company
    • 17.3.16. GenScript Biotech Corporation
    • 17.3.17. Gilead Sciences, Inc.
    • 17.3.18. HOLOSTEM S.r.l. by Chiesi Farmaceutici S.p.A
    • 17.3.19. JCR Pharmaceuticals Co., Ltd.
    • 17.3.20. Lineage Cell Therapeutics, Inc.
    • 17.3.21. Lonza Group
    • 17.3.22. Merck KGaA
    • 17.3.23. Novartis AG
    • 17.3.24. Novo Holdings A/S
    • 17.3.25. NuVasive Inc.
    • 17.3.26. Pluristyx, Inc.
    • 17.3.27. Sartorius AG
    • 17.3.28. STEMCELL Group of Companies
    • 17.3.29. Takeda Pharmaceutical Company Limited
    • 17.3.30. Thermo Fisher Scientific Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES STEM CELLS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES STEM CELLS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. STEM CELLS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. STEM CELLS MARKET: RESEARCHAI
  • FIGURE 28. STEM CELLS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. STEM CELLS MARKET: RESEARCHCONTACTS
  • FIGURE 30. STEM CELLS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STEM CELLS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELLS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELLS MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELLS MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELLS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELLS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELLS MARKET SIZE, BY BIOPRINTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELLS MARKET SIZE, BY BIOPRINTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELLS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELLS MARKET SIZE, BY CELL CULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELLS MARKET SIZE, BY 2D CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELLS MARKET SIZE, BY 2D CULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELLS MARKET SIZE, BY 3D CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELLS MARKET SIZE, BY 3D CULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELLS MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELLS MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELLS MARKET SIZE, BY CRISPR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELLS MARKET SIZE, BY CRISPR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL STEM CELLS MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STEM CELLS MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL STEM CELLS MARKET SIZE, BY AMNIOTIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STEM CELLS MARKET SIZE, BY AMNIOTIC CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL STEM CELLS MARKET SIZE, BY CELL BANKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STEM CELLS MARKET SIZE, BY CELL BANKING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL STEM CELLS MARKET SIZE, BY PRIVATE BANKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STEM CELLS MARKET SIZE, BY PRIVATE BANKING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL STEM CELLS MARKET SIZE, BY PUBLIC BANKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STEM CELLS MARKET SIZE, BY PUBLIC BANKING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL STEM CELLS MARKET SIZE, BY PHARMACEUTICAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STEM CELLS MARKET SIZE, BY PHARMACEUTICAL SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL STEM CELLS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STEM CELLS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL STEM CELLS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STEM CELLS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL STEM CELLS MARKET SIZE, BY ORTHOPAEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STEM CELLS MARKET SIZE, BY ORTHOPAEDICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL STEM CELLS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STEM CELLS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL STEM CELLS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL STEM CELLS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL STEM CELLS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL STEM CELLS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL STEM CELLS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL STEM CELLS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS STEM CELLS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES STEM CELLS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES STEM CELLS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 183. MEXICO STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 193. BRAZIL STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 195. BRAZIL STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 203. BRAZIL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 204. BRAZIL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 205. BRAZIL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 206. BRAZIL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 207. BRAZIL STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 213. ARGENTINA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. ARGENTINA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 215. ARGENTINA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 216. ARGENTINA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 217. ARGENTINA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 218. ARGENTINA STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 219. ARGENTINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 220. ARGENTINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 223. ARGENTINA STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 224. ARGENTINA STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 225. ARGENTINA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 226. ARGENTINA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 227. ARGENTINA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 228. ARGENTINA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 229. ARGENTINA STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ARGENTINA STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED KINGDOM STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED KINGDOM STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED KINGDOM STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED KINGDOM STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED KINGDOM STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 277. GERMANY STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 280. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 281. GERMANY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. GERMANY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 283. GERMANY STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 285. GERMANY STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 287. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 289. GERMANY STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. GERMANY STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 293. GERMANY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 294. GERMANY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 295. GERMANY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 297. GERMANY STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 299. FRANCE STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 302. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 303. FRANCE STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 305. FRANCE STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 307. FRANCE STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 309. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 311. FRANCE STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. FRANCE STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 313. FRANCE STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 314. FRANCE STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 315. FRANCE STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 316. FRANCE STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 317. FRANCE STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 318. FRANCE STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 319. FRANCE STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. FRANCE STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 321. RUSSIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. RUSSIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 324. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 325. RUSSIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. RUSSIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 327. RUSSIA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 328. RUSSIA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 329. RUSSIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 330. RUSSIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 331. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 332. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 333. RUSSIA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. RUSSIA STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 335. RUSSIA STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 336. RUSSIA STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 337. RUSSIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 338. RUSSIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 339. RUSSIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 340. RUSSIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 341. RUSSIA STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. RUSSIA STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 343. ITALY STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. ITALY STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 345. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 346. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 347. ITALY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 348. ITALY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 349. ITALY STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 350. ITALY STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 351. ITALY STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 352. ITALY STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 353. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 354. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 355. ITALY STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 356. ITALY STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 357. ITALY STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 358. ITALY STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 359. ITALY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 360. ITALY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 361. ITALY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 362. ITALY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 363. ITALY STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 364. ITALY STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 365. SPAIN STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 366. SPAIN STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 367. SPAIN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 368. SPAIN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 369. SPAIN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 370. SPAIN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 371. SPAIN STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILL